Sage Bionetworks, the Seattle-based nonprofit seeking to spark an open source movement for biology, said today it has begun work for a couple of partners—Japan-based Takeda Pharmaceutical and the CHDI Foundation. Both projects involve building computational models for neurological diseases. Takeda said it November that it agreed to pay $3.6 million over four years to support the research. Sage didn’t disclose the terms of CHDI’s support in today’s statement, although Sage said it is working with Massachusetts General Hospital to analyze tissues from Huntington’s disease patients. Sage also recently received support from pharmaceutical giant AstraZeneca to perform cancer research.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
